Results 311 to 320 of about 289,605 (341)
Some of the next articles are maybe not open access.
Immunotherapy in Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A subset of TNBC is immune activated, suggesting that immunotherapy may be a viable treatment strategy. Phase III clinical trials have shown that atezolizumab or pembrolizumab is well-tolerated in combination with chemotherapy, with progression-free ...
openaire +2 more sources
Triple-negative breast cancers
Expert Review of Anticancer Therapy, 2023Steven A, Narod, Rebecca, Dent
openaire +2 more sources
2016
Breast cancer is a heterogeneous disease consisting of distinct biological subtypes and triple-negative breast cancers (TNBC) are those that lack expression of the breast cancer prognostic markers ER, PR and HER2. TNBC often follows an aggressive disease course with poorer disease-specific survival compared to other breast cancer subtypes.
openaire +1 more source
Breast cancer is a heterogeneous disease consisting of distinct biological subtypes and triple-negative breast cancers (TNBC) are those that lack expression of the breast cancer prognostic markers ER, PR and HER2. TNBC often follows an aggressive disease course with poorer disease-specific survival compared to other breast cancer subtypes.
openaire +1 more source
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Nature Reviews Clinical Oncology, 2021G. Bianchini +3 more
semanticscholar +1 more source
Less Common Triple-Negative Breast Cancers
2016This chapter encompasses four uncommon types of triple negative breast cancer, which include adenoid cystic carcinoma (ACC), apocrine carcinoma, metaplastic carcinoma, and medullary carcinoma. Also included in the discussion for differential diagnosis are three additional rare subtypes: acinic cell carcinoma, oncocytic carcinoma, and mucoepidermoid ...
Poonam Vohra +2 more
openaire +1 more source
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
New England Journal of Medicine, 2019H. O’sullivan, D. Collins, S. O'Reilly
semanticscholar +1 more source